Claims for Patent: 11,400,090

Summary for Patent: 11,400,090

Title:	Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
Abstract:	The present invention provides a medicament for the treatment or prevention of a cell proliferative disorder, the medicament comprising as an active ingredient a compound represented by formula or a pharmaceutically acceptable salt thereof, wherein the medicament is used in such a manner that: (a) said compound or salt is administered twice weekly for 3 weeks, (b) administration of said compound or salt is paused for the following 1 week, and (c) steps (a) and (b) are subsequently repeated at least once.
Inventor(s):	Udai BANERJI
Assignee:	Institute of Cancer Research , Royal Marsden NHS Foundation Trust
Application Number:	US16/764,242
Patent Claims:	1. A method for the treatment of a cell proliferative disorder selected from the group consisting of HRAS mutant cancer, KRAS mutant cancer and NRAS mutant cancer, the method comprising: (a) administering a compound represented by formula (I): or a pharmaceutically acceptable salt thereof twice weekly for 3 weeks, (b) pausing administration of said compound or salt for the following 1 week, and (c) subsequently repeating steps (a) and (b) at least once. 2. The method according to claim 1, wherein a potassium salt of a compound represented by formula (I) is administered. 3. The method according to claim 1, wherein the cell proliferative disorder is an HRAS mutant cancer or an NRAS mutant cancer. 4. The method according to claim 1, wherein the cell proliferative disorder is a KRAS mutant cancer. 5. The method according to claim 1, wherein the cell proliferative disorder is a solid cancer. 6. The method according to claim 1, wherein the dose per administration in step (a) is 3.2 mg. 7. The method according to claim 6, wherein the method comprises, prior to step (a): (1) administering said compound or salt twice weekly at a dose of 3.2 mg per administration; or (2) (2a) administering said compound or salt twice weekly for 3 weeks at a dose of 4 mg per administration, (2b) pausing administration of said compound or salt for the following 1 week, and (2c) subsequently repeating steps (2a) and (2b) at least once. 8. The method according to claim 7, wherein the method comprises, prior to step (1) or (2), administering said compound or salt twice weekly at a dose of 4 mg per administration. 9. The method according to claim 1: wherein the method comprises: (A) first, administering said compound or salt twice weekly at a dose of 4 mg per administration, (B1) next, administering said compound or salt twice weekly at a dose of 3.2 mg per administration, and (C) then: (Ca) administering said compound or salt twice weekly for 3 weeks at a dose of 3.2 mg per administration, (Cb) pausing administration of said compound or salt for the following 1 week, and (Cc) subsequently repeating steps (Ca) and (Cb) at least once; or wherein the method comprises: (A) first, administering said compound or salt twice weekly at a dose of 4 mg per administration, and (B2) next: (B2a) administering said compound or salt twice weekly for 3 weeks at a dose of 4 mg per administration, (B2b) pausing administration of said compound or salt for the following 1 week, and (B2c) subsequently repeating steps (B2a) and (B2b) at least once; or wherein the method comprises: (A) first, administering said compound or salt twice weekly at a dose of 4 mg per administration, (B2) next: (B2a) administering said compound or salt twice weekly for 3 weeks at a dose of 4 mg per administration, (B2b) pausing administration of said compound or salt for the following 1 week, and (B2c) subsequently repeating steps (B2a) and (B2b) at least once, and (C) then: (Ca) administering said compound or salt twice weekly for 3 weeks at a dose of 3.2 mg per administration, (Cb) pausing administration of said compound or salt for the following 1 week, and (Cc) subsequently repeating steps (Ca) and (Cb) at least once. 10. The method according to claim 1, wherein the cell proliferative disorder is multiple myeloma. 11. The method according to claim 10, wherein the dose per administration in step (a) is 4 mg. 12. The method according to claim 10, wherein the cell proliferative disorder is an NRAS mutant cancer. 13. The method according to claim 10, wherein said compound or salt is used in combination with dexamethasone, and wherein the method comprises administering said compound or salt before, simultaneously with or after administration of dexamethasone. 14. The method according to claim 13, wherein dexamethasone is administered once weekly at a dose of 20 mg per administration. 15. The method according to claim 1, wherein the administration of said compound or salt is oral administration.